SCHEMBL8263284

SCHEMBL8263284

Clc1ccnc(CNCCN2CCOCC2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.47
ALDH1A1 P00352 3/20 0.47
CYP2D6 P10635 3/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C19 P33261 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.46
TSHR P16473 2/20 0.46
CYP1A2 P05177 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALOX15 P16050 1/20 0.46
MEN1 O00255 1/20 0.46
MITF O75030 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
SMARCA2 P51531 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 1/20 0.45
CNR1 P21554 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12845767 0.92 CYP2C19 (0.57) POLBALDH1A1CYP2D6CYP3A4CYP2C19
SCHEMBL5013030 0.80 ALDH1A1 (0.71) POLBALDH1A1CYP2D6CYP3A4CYP2C19
SCHEMBL5117431 0.79 CYP2A13 (0.54) L3MBTL1TSHRHTTNPSR1KDM4E
SCHEMBL29774129 0.74 L3MBTL1 (0.42) POLBALDH1A1L3MBTL1CYP1A2MEN1
SCHEMBL8263259 0.74 ACKR3 (0.52) POLBCYP3A4HTTNPSR1MEN1
SCHEMBL8264776 0.73 NPSR1 (0.44) POLBALDH1A1CYP2D6CYP3A4CYP2C19
SCHEMBL620364 0.73 ALDH1A1 (0.62) ALDH1A1CYP2C19LMNAKMT2ASMN1; SMN2
SCHEMBL7681152 0.73 CYP2D6 (0.55) POLBALDH1A1CYP2D6CYP3A4CYP2C19
SCHEMBL31352463 0.73 KDM4E (0.57) POLBALDH1A1CYP2D6CYP3A4CYP2C19
SCHEMBL13656933 0.72 L3MBTL1 (0.42) POLBALDH1A1CYP2D6CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404683-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICAL N.V. (BE) 2013-03-26 US disclosed
US-20110053937-A1 Inhibitors of the Interaction Between MDM2 and P53 LACRAMPE JEAN FERNAND ARMAND 2011-03-03 US disclosed
US-7834016-B2 Inhibitors of the interaction between MDM2 and p53 JANSSEN PHARMACEUTICA NV (BE) 2010-11-16 US disclosed
US-7834016-B2 Inhibitors of the interaction between MDM2 and p53 JANSSEN PHARMACEUTICA NV (BE) 2010-11-16 US disclosed
US-20080039472-A1 Inhibitors of the Interaction Between Mdm2 and P53 JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-14 US disclosed
US-20080039472-A1 Inhibitors of the Interaction Between Mdm2 and P53 JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-14 US disclosed
WO-2006032631-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053937-A1 Inhibitors of the Interaction Between MDM2 and P53 TP53, MDM2, TP53BP1 POLB 1555/4885ALDH1A1 4018/4885CYP2D6 1520/4885
US-20080039472-A1 Inhibitors of the Interaction Between Mdm2 and P53 TP53, MDM2, TP53BP1 POLB 1555/4885ALDH1A1 4018/4885CYP2D6 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.